Carpenter D. Visions of the Republic: Petitions, Associations and Elections in Early America.; In Press.

Carpenter D, Tobbell D. “Bioequivalence: The Regulatory Career of a Pharmaceutical Concept” . Bulletin of the History of Medicine. Submitted.

Carpenter D, Grimmer J, Lomazoff E. “Approval Regulation and Endogenous Consumer Confidence: Theory and an Analogies to Licensing, Safety and Financial Regulation” . Regulation and Governance . 2010;4(4).

Carpenter D, Moffitt S, Moore C, Rynbrandt R, Ting M, Yohai I, Zucker EJ. “Early-Entrant Protection in Approval Regulation: Theory and Evidence from FDA Drug Review”. Journal of Law Economics and Organization . 2010;26(2).

“Institutional Strangulation: Bureaucratic Politics and Financial Reform in the Obama Administration” . Perspective on Politics. 2010;8(3):825-46.

Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA. Princeton: Princeton University Press; 2010. Website

Carpenter D. “Reputation Information and Confidence – The Political Economy of Pharmaceutical Regulation” . Public Choice and Public Law . 2010.

Carpenter D, Keyhani S, Anderson G, Hebert P, Wang S. “U.S. Pharmaceutical Innovation in an International Context” . American Journal of Public Health [Internet]. 2010;(6):1075-1080. Website

Carpenter D. “Confidence Games: How Does Regulation Constitute Markets?”. In: Balleisen E, Moss D Towards a New Theory of Regulation. New York : Cambridge University Press; 2009.

Carpenter D. “Regulation” . In: Kazin M The Princeton Encyclopedia of Political History . ; 2009.

Carpenter D, Zucker EJ, Avorn J. “Drug Review Deadlines and Subsequent Safety Problems”. New England Journal of Medicine . 2008;358(13):1354-61.

Carpenter D, Volden C, Ting M. “A Formal Model of Learning and Policy Diffusion” . American Political Science Review . 2008;102 (3):319-32.

Carpenter D. “The Leaning Tower of PISA: Fundamental Problems in Ignorance-Based Theories of State Autonomy” . Critical Review . 2007.

Carpenter D, Sin G. “Policy Tragedy and the Emergence of Regulation: The Food Drug and Cosmetic Act of 1938” . Studies in American Political Development . 2007;21(2):149-180.

Carpenter D, Ting M. “Regulatory Errors with Endogenous Agendas”. American Journal of Political Science . 2007;51(4):835-853.

Carpenter D, Moore CD. “Robust Action and the Strategic Use of Ambiguity in a Bureaucratic Cohort: FDA Scientists and the Investigational New Drug Regulations of 1963” . In: Glassman M, Skowronek S Formative Acts: American Politics in the Making . University of Pennsylvania Press ; 2007.

Carpenter D. “Reputation Gatekeeping and the Politics of Post-marketing Drug Regulation”. Virtual Mentor [American Medical Association] [Internet]. 2006;8:403-406. Website

Carpenter D, Armstrong E, Hojnacki M. “Whose Deaths Matter? Mortality Identity and Attention to Disease in the Mass Media” . Journal of Health Politics Policy and Law . 2006;31(4):729-772.

Carpenter D. “The Evolution of National Bureaucracy in the United States” . In: Aberbach JD, Peterson M, of Branch TIAD: TE New York: Oxford University Press ; 2005. p. 41-71.

Carpenter D. “A Modest Proposal for Financing Postmarketing Drug Safety Studies by Augmenting FDA User Fees” . Health Affairs – Web Exclusive . 2005;W5 (469).